The first vancomycin-resistant clinical isolates of Enterococcus species were reported in Europe in 1988. Similar strains were later detected in hospitals on the East Coast of the United States. Since then, vancomycin-resistant enterococci have spread with unexpected rapidity and are now encountered in hospitals in most countries. This article reviews the mode of action and the mechanism of bacterial resistance to glycopeptides, as exemplified by the VanA type, which is mediated by transposon Tn1546 and is widely spread in enterococci. The diversity, regulation, evolution, and recent dissemination of methicillin-resistant Staphylococcus aureus are then discussed. 
Vancomycin binds with high affinity to the d-Alad-Ala C-terminus of the pentapeptide, thus blocking the addition of late precursors by transglycosylation to the nascent peptidoglycan chain and preventing subsequent cross-linking by transpeptidation (figure 1) [5] . Vancomycin does not penetrate into the cytoplasm; therefore, interaction with its target can take place only after translocation of the precursors to the outer surface of the membrane.
MECHANISM OF RESISTANCE TO VANCOMYCIN
Because vancomycin does not interact with cell wall biosynthetic enzymes but forms complexes with peptidoglycan precursors, its activity is not determined by the affinity for a target enzyme but by the substrate specificity of the enzymes that determine the structure of peptidoglycan precursors. Resistance to vancomycin is due to the presence of operons that encode enzymes (1) for synthesis of low-affinity precursors, in which the C-terminal d-Ala residue is replaced by d-lactate (d-Lac) or d-serine (d-Ser), thus modifying the vancomyin-binding target; and (2) for elimination of the high-affinity precursors that are normally produced by the host, thus removing the vancomycin-binding target [6] .
Target modification. VanA-type resistance, which is characterized by inducible high levels of resistance to vancomycin and teicoplanin (table 1), was the first type of resistance described and is mediated by transposon Tn1546 and elements closely related to it. The transposon encodes a dehydrogenase (VanH), which 
reduces pyruvate to d-Lac, and the VanA ligase, which catalyzes the formation of an ester bond between d-Ala and d-Lac (figure 2) [6] . The resulting d-Ala-d-Lac depsipeptide replaces the dAla-d-Ala dipeptide in peptidoglycan synthesis, a substitution that decreases the affinity of the molecule for glycopeptides considerably [7] . The VanC resistance phenotype was described first in Enterococcus gallinarum [8] and then in the Enterococcus casseliflavus-Enterococcus flavescens [9] species, which possess intrinsic low levels of resistance to vancomycin and are susceptible to teicoplanin (table 1) [10] . Substitution of the ultimate dAla by a d-Ser results in steric hindrance that reduces its affinity for vancomycin [11] .
Removal of the susceptible target. The simultaneous production of precursors ending in d-Ala or d-Lac does not lead 
Organization of the vanA operon. Open arrows represent coding sequences and indicate the direction of transcription. The regulatory and resistance genes are cotranscribed from promoters P R and P H , respectively.
to resistance [12] . Under these conditions, binding of glycopeptides to precursors that contain d-Ala-d-Ala inhibits peptidoglycan synthesis. The interaction of vancomycin with its target is prevented by the removal of the susceptible precursors that terminate in d-Ala [13] . Two enzymes are involved in this process (figure 2): the VanX D,D-dipeptidase, which hydrolyzes the d-Ala-d-Ala dipeptide synthesized by the host d-Ala:d-Ala ligase (Ddl) [14] , and the VanY D,D-carboxypeptidase, which removes the C-terminal d-Ala residue of late peptidoglycan precursors when elimination of d-Ala-d-Ala by VanX is incomplete [15] . As opposed to VanA-type resistance, in which the VanX and VanY activities are catalyzed by 2 enzymes (figure 2) [15] , VanXY C has both D,D-dipeptidase and D,D-carboxypeptidase activity (figure 3) [16] .
Types of resistance. Six types of vancomycin resistance have been characterized on both a phenotypic and a genotypic basis in enterococci (table 1). Five of these types (VanA, B, D, E, and G) correspond to acquired resistance; one type (VanC) is an intrinsic property of E. gallinarum and E. casseliflavus-E. flavescens. Classification of glycopeptide resistance is currently based on the primary sequence of the structural genes for the resistance ligases rather than on the levels of resistance to glycopeptides, because the MIC ranges of vancomycin and teicoplanin against the various types overlap (table 1). VanA-type strains display high levels of inducible resistance to both vancomycin and teicoplanin, whereas VanB-type strains have variable levels of inducible resistance to vancomycin only [12] .
VanD-type strains are characterized by constitutive resistance to moderate levels of the 2 glycopeptides [17] . VanC-, VanE-, and VanG-type strains are resistant to low levels of vancomycin but remain susceptible to teicoplanin [10] .
Although the 6 types of resistance involve related enzymatic functions, they can be distinguished by the location of the corresponding genes and by the mode of regulation of gene expression. The vanA and vanB operons are located on plasmids or in the chromosome [6] , whereas the vanD [17] , vanC [18] , vanE [19] , and vanG [20] operons have, thus far, been found only in the chromosome.
VanA. VanA is the most frequently encountered type of glycopeptide resistance in enterococci and, to date, is the only one detected in Staphylococcus aureus (table 1; figure 2 ). The prototype Tn1546 VanA-type resistance element, which was originally detected on a plasmid in an Enterococcus faecium clinical isolate, is an 11-kb transposon. It encodes 9 polypeptides that can be assigned to various functional groups: transposition (ORF1 and ORF2), regulation of resistance gene expression The VanR and VanS proteins are part of a 2-component regulatory system that modulates transcription of the resistance gene cluster [21] . This system is composed of a cytoplasmic VanR response regulator, which acts as a transcriptional activator, and a membrane-bound VanS histidine kinase (figure 4). The vanA gene cluster has been found mainly in E. faecium and Enterococcus faecalis but also in Enterococcus avium, Enterococcus durans, Enterococcus raffinosus, and atypical isolates of E. gallinarum and E. casseliflavus, which are highly resistant to both vancomycin and teicoplanin.
VanB. As in VanA-type strains, acquired VanB-type resistance is due to synthesis of peptidoglycan precursors ending [12] . The organization and functionality of the vanB cluster is similar to that of vanA but differs in its regulation, because vancomycin, but not teicoplanin, is an inducer of the vanB cluster (table 1). The vanB operon contains genes encoding a dehydrogenase, a ligase, and a dipeptidase, all of which have a high level of sequence identity (67%-76% identity) with 
the corresponding deduced proteins of the vanA operon and the vanR B S B regulatory genes that encode a 2-component system only distantly related to VanRS (34% and 24% identity) [22] . The function of the additional VanW protein found only in the vanB cluster is unknown, and there is no gene related to vanZ. On the basis of sequence differences, the vanB gene cluster can be divided into 3 subtypes: vanB1, vanB2, and vanB3 [23, 24] . There is no correlation between the vanB subtype and the level of resistance to vancomycin.
VanD. Acquired VanD-type resistance is due to constitutive production of peptidoglycan precursors ending in d-Ala-d-Lac (table 1) [17] . The organization of the vanD operon, which is located exclusively in the chromosome in strains that have been studied, is similar to that of vanA and vanB [17] . However, no genes homologous to vanZ or vanW from the vanA and vanB operons, respectively, are present. VanD-type strains share other characteristics that distinguish them from VanA-and VanBtype enterococci. Resistance is constitutive and is not transferable by conjugation to other enterococci [17] . VanD-type strains have negligible D,D-dipeptidase activity, which should result in a susceptible phenotype, because these bacteria are unable to eliminate peptidoglycan precursors ending in d-Alad-Ala, which is the target for glycopeptides. However, in VanDtype strains, the susceptible pathway does not function, because the Ddl is inactive as the result of various mutations in the chromosomal ddl gene (figure 5) [17, 25] . The gene can be disrupted by a 5-bp insertion, insertion of the IS19 element, or a point mutation. Consequently, the strains should grow only in the presence of vancomycin, because they rely on the inducible resistance pathway for peptidoglycan synthesis. However, this is not the case because the vanD clusters are expressed constitutively as a result of mutations (frameshift or point mutation or insertion-inactivation) in the VanS D sensor or a point mutation in the VanR D regulator [17, 25] .
Another unusual feature of VanD-type strains is their only slightly diminished susceptibility to teicoplanin (MIC, 4 mg/mL) (table 1) despite their constitutive production of peptidoglycan precursors that terminate mainly in d-Ala-d-Lac. VanD-type strains that constantly activate the vanD operon, by mutation in the 2-component regulatory system, and that have eliminated the susceptible pathway, by inactivation of the Ddl, provide a remarkable example of "tinkering" in both intrinsic and acquired genes to achieve higher levels of antibiotic resistance.
VanC. E. gallinarum and E. casseliflavus-E. flavescens are intrinsically resistant to low levels of vancomycin but remain susceptible to teicoplanin (table 1 3). In the vanA, vanB, and vanD clusters, the genes encoding the 2-component regulatory systems (i.e., VanRS, VanR B S B , or VanR D S D ) are located upstream from the resistance genes (figure 2), whereas, in the vanC cluster, these genes are downstream from vanT (figure 3). The deduced proteins of the vanC-2 operon from E. casseliflavus display high degrees of identity (71%-91% identity) with those encoded by the vanC operon, and those of the vanC-3 gene cluster from E. flavescens display extensive identity with vanC-2 (97%-100% identity), including the intergenic regions [26] . It is, therefore, difficult to distinguish between E. casseliflavus and E. flavescens as 2 different species [26] .
VanE. The VanE phenotype corresponds to low-level resistance to vancomycin and susceptibility to teicoplanin due to synthesis of peptidoglycan precursors terminating in d-Ala-dSer as in intrinsically resistant Enterococcus species (table 1). The vanE cluster has an organization identical to that of the vanC operon [19] .
VanG. Acquired VanG type is characterized by resistance to low levels of vancomycin (MIC, 16 mg/mL) but susceptibility to teicoplanin (MIC, 0.5 mg/mL) [27] and by inducible synthesis of peptidoglycan precursors ending in d-Ala-d-Ser (table 1) . The chromosomal vanG cluster is composed of 7 genes recruited from various van operons [20] . In contrast to the other van operons, the cluster contains 3 genes (vanU G , vanR G , and vanS G ) encoding a putative regulatory system. vanR G and vanS G have the highest similarity to vanR D and vanS D , and the additional vanU G gene encodes a predicted transcriptional activator. A protein of this type has not previously been associated with glycopeptide resistance.
Glycopeptide-dependent strains. An intriguing and clinically important phenomenon that has developed in some VanAand VanB-type enterococci is vancomycin dependence ( figure  6 ). These strains are not only resistant to vancomycin or to both vancomycin and teicoplanin, but also require their presence for growth. Variants of glycopeptide-resistant E. faecalis and E. faecium that grow only in the presence of glycopeptides have been isolated in vitro, in animal models, and from patients treated with vancomycin for long periods [28, 29] . In the presence of vancomycin, the vanA-or vanB-encoded d-Ala:d-Lac ligase is induced, which overcomes the defect in synthesis of peptidoglycan precursors ending in d-Ala-d-Ala because of the lack of a functional Ddl following various mutations in the ddl gene and, thus, permits growth of the bacteria [29] . Because these strains require particular growth conditions, their prevalence is probably underestimated and not easily detected by routine laboratory testing. Reversion to vancomycin independence has been observed and occurs as a result of a mutation in either the VanS or VanS B sensor, which leads to constitutive production of d-Ala-d-Lac and, thus, to teicoplanin resistance, or in the ddl gene, which restores synthesis of d-Ala-d-Ala and leads to a VanB phenotype inducible by vancomycin [29] .
Regulation of resistance. Expression of glycopeptide resistance is regulated by a VanS/VanR-type 2-component signaltransduction system composed of a membrane-bound histidine kinase and a cytoplasmic response regulator that acts as a tran- scriptional activator (figure 4) [21] . VanS-type sensors comprise an N-terminal glycopeptide sensor domain with 2 membranespanning segments and a C-terminal cytoplasmic kinase domain (figure 4). After a signal associated with the presence of a glycopeptide in the culture medium, the cytoplasmic domain of VanS catalyzes ATP-dependent autophosphorylation on a specific histidine residue and transfers the phosphate group to an aspartate residue of VanR present in the effector domain (figure 7) [21] . VanS also stimulates dephosphorylation of VanR in the absence of glycopeptide [30] . The VanS sensor therefore modulates the phosphorylation level of the VanR regulator: it acts as a phosphatase under noninducing conditions and as a kinase in the presence of glycopeptides, leading to phosphorylation of the response regulator and activation of the resistance genes (figure 7) [30] .
GENETICS OF THE VAN OPERONS
vanA Operon. The vanA gene cluster was detected originally on the nonconjugative Tn1546 transposon [31] . VanA-type resistance in clinical isolates of enterococci is mediated by genetic elements, identical or closely related to Tn1546, that are generally carried by self-transferable plasmids [1] and, occasionally, by the host chromosome as part of larger conjugative elements [32] . Tn1546-like elements are highly conserved, except for the presence of insertion sequences that have transposed into intergenic regions that are not essential for expression of glycopeptide resistance. Conjugal transfer of plasmids that have acquired Tn1546-like elements by transposition appears to be responsible for the spread of glycopeptide resistance in enterococci.
vanB Operon. Gene clusters related to vanB are generally carried by large (90-250-kb) elements that are transferable by conjugation from chromosome to chromosome [33] . Plasmidborne vanB clusters have also been detected in clinical isolates of enterococci [34] . Much of the dissemination of VanB-type resistance appears to have resulted from the spread of vanB2 clusters carried on Tn916-like conjugative transposons. Two related elements, Tn5382 (27 kb in size) [35] and Tn1549 (34 kb in size) [36] , have been identified widely in the United States and in Europe.
vanG Operon. Transfer of VanG-type resistance is associated with the movement, from chromosome to chromosome, of genetic elements of ∼240 kb that also carry ermB-encoded erythromycin resistance [20] .
Glycopeptide resistance in S. aureus. The transfer of van resistance genes from Enterococcus species to S. aureus, which results in high levels of resistance to vancomycin, was obtained in vitro and in an animal model [37] . Most important, this transfer also occurs in vivo. Recently, 3 methicillin-resistant S. aureus (MRSA) isolates with high or moderate levels of resistance to vancomycin and teicoplanin have been isolated from patients in Michigan (MI-VRSA), Pennsylvania (PA-VRSA), and New York after acquisition of the vanA gene cluster [38] [39] [40] .
Clinical isolate MI-VRSA is highly resistant to both glycopeptides [40] , whereas PA-VRSA [39] and the New York VRSA strain [38] are moderately resistant to vancomycin and have reduced susceptibility to teicoplanin (figure 8). The 3 isolates harbor a plasmidborne Tn1546 element [41] [42] [43] . A vancomycin-resistant E. faecalis strain and a vancomycin-susceptible MRSA strain (MI-MRSA) were isolated from the same patient as MI-VRSA and are considered to be the Tn1546 donor and recipient, respectively [40] . The vancomycin-resistant E. faecalis strain from Michigan harbors a broad-host-range plasmid that contains a copy of Tn1546 [44] , and strain MI-MRSA also contains a resident plasmid. In MI-VRSA, the Tn1546 element is borne by a plasmid that is identical to the resident plasmid in MI-MRSA except for a copy of Tn1546. Therefore, the Enterococcus plasmid apparently behaved as a suicide Tn1546 delivery vector to the plasmid in MI-MRSA [43] . Analysis of the nucleotide sequences flanking Tn1546 indicated that the transposon was flanked by 5-bp duplications of target DNA [45] typical of the Tn3 family of elements [46] to which Tn1546 belongs [31] . This observation confirms that Tn1546 has transposed into the plasmid of MI-MRSA. Comparative analysis of peptidoglycan precursors and of D,D-dipeptidase (VanX) and D,D-carboxypeptidase (VanY) activities indicated high similar levels of expression of the vanA gene clusters in the MI-VRSA and PA-VRSA strains. Thus, the difference in glycopeptide resistance between the 2 isolates is not due to a difference in van gene expression.
The stability of the vanA operon was studied in MI-VRSA and PA-VRSA by replica plating. No vancomycin-susceptible clones of MI-VRSA were obtained, whereas ∼50% of the PA-VRSA derivatives were susceptible after overnight growth in the absence of vancomycin. In MI-VRSA, transposition of Tn1546 from the enterococcal to the resident plasmid rescued the incoming genetic information, whereas, in PA-VRSA, gly-copeptide resistance is due to the acquisition of a large plasmid, presumably also from Enterococcus species, that probably does not replicate efficiently in the new host.
The effect of prior induction by vancomycin on growth of the MI-VRSA and PA-VRSA isolates indicated that, as opposed to MI-VRSA, when PA-VRSA was grown overnight in the absence or presence of antibiotic and was subcultured with vancomycin, growth was delayed for a minimum of 8 h ( figure 9 ). Taken together, these data suggest that low-level vancomycin resistance of the PA-VRSA strain, and maybe also of the New York VRSA strain, could be due to a longer delay in induction of resistance associated with a high rate of spontaneous loss of the vancomycin resistance determinant or to a low rate of loss of a resistance trait with high biological cost [45] .
CONCLUSIONS
Major advances in the understanding of the biochemical mechanisms and genetics of vancomycin resistance in enterococci have been achieved. However, the origin of the resistance genes remains unclear. The glycopeptide-producing organisms, which have to protect themselves against the products of their secondary metabolism, represent a potential source for resistance because they harbor genes encoding homologues of VanS, VanR, VanH, VanA, and VanX [47] . Alternately, the vancomycin-resistant biopesticide Paenibacillus popilliae, which contains the vanF operon related to the vanA cluster, could be the progenitor of the resistance genes acquired by enterococci [48] .
Glycopeptides, alone or in combination, often constitute the only therapy for infection with multiresistant strains of staphylococci, streptococci, and enterococci. The emergence and dissemination of high-level resistance to vancomycin in enterococci can lead to clinical isolates resistant to all antibiotics. Although enterococci are not highly pathogenic, the incidence of vancomycin resistance among clinical isolates is steadily increasing, and such isolates have become important as nosocomial pathogens and as a reservoir of resistance genes. Dissemination of glycopeptide resistance to more pathogenic bacteria, such as staphylococci and streptococci, has occurred, because there is no barrier to heterospecific expression or gene transfer among gram-positive cocci. Such a transfer in nature may be underestimated because of low-level phenotypic expression in the new host. The 16-year delay in detection of VanA-type resistance in S. aureus and its apparent rarity could be due to inefficient replication of enterococcal plasmids in staphylococci. Thus, the efficacy of glycopeptide resistance transfer from Enterococcus species to Staphylococcus species, similar to the transfer to gram-negative bacteria [49] , results from the combined multiplicative probabilities of the transfer process and of the mechanism of stabilization of exogenous DNA. The frequency of the second event is very low, because transposons of the Tn3 family, Tn1546 in particular [31] , are very stable genetic elements.
